Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury.
Alvarez XA, Sampedro C, Figueroa J, Tellado I, González A, García-Fantini M, Cacabelos R, Muresanu D, Moessler H. Alvarez XA, et al. Among authors: moessler h. J Neural Transm (Vienna). 2008 May;115(5):683-92. doi: 10.1007/s00702-008-0024-9. Epub 2008 Feb 14. J Neural Transm (Vienna). 2008. PMID: 18273537 Clinical Trial.
Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.
Alvarez XA, Sampedro C, Pérez P, Laredo M, Couceiro V, Hernández A, Figueroa J, Varela M, Arias D, Corzo L, Zas R, Lombardi V, Fernández-Novoa L, Pichel V, Cacabelos R, Windisch M, Aleixandre M, Moessler H. Alvarez XA, et al. Among authors: moessler h. Int Clin Psychopharmacol. 2003 Sep;18(5):271-8. doi: 10.1097/00004850-200309000-00003. Int Clin Psychopharmacol. 2003. PMID: 12920387 Clinical Trial.
A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. Alvarez XA, et al. Among authors: moessler h. Eur J Neurol. 2006 Jan;13(1):43-54. doi: 10.1111/j.1468-1331.2006.01222.x. Eur J Neurol. 2006. PMID: 16420392 Clinical Trial.
Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H. Alvarez XA, et al. Among authors: moessler h. Eur J Neurol. 2011 Jan;18(1):59-68. doi: 10.1111/j.1468-1331.2010.03092.x. Eur J Neurol. 2011. PMID: 20500802 Clinical Trial.
Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.
Alvarez XA, Alvarez I, Martinez A, Romero I, Benito C, Suarez I, Mourente S, Fantini M, Figueroa J, Aleixandre M, Linares C, Muresanu D, Winter S, Moessler H. Alvarez XA, et al. Among authors: moessler h. Int J Neuropsychopharmacol. 2020 Dec 3;23(9):581-586. doi: 10.1093/ijnp/pyaa046. Int J Neuropsychopharmacol. 2020. PMID: 32640027 Free PMC article.
53 results